Format

Send to

Choose Destination
Euro Surveill. 2017 Oct;22(43). doi: 10.2807/1560-7917.ES.2017.22.43.17-00707.

Low interim influenza vaccine effectiveness, Australia, 1 May to 24 September 2017.

Author information

1
Discipline of General Practice, University of Adelaide, Australia.
2
School of Global and Population Health, University of Melbourne, Australia.
3
WHO Collaborating Centre for Reference and Research on Influenza, Melbourne, Australia.
4
Victorian Infectious Diseases Reference Laboratory, Melbourne, Australia.
5
SA Pathology, Adelaide, Australia.
6
PathWest Laboratory Medicine WA, Perth, Australia.
7
School of Biomedical Sciences, Monash University, Melbourne, Australia.

Abstract

In 2017, influenza seasonal activity was high in the southern hemisphere. We present interim influenza vaccine effectiveness (VE) estimates from Australia. Adjusted VE was low overall at 33% (95% confidence interval (CI): 17 to 46), 50% (95% CI: 8 to 74) for A(H1)pdm09, 10% (95% CI: -16 to 31) for A(H3) and 57% (95% CI: 41 to 69) for influenza B. For A(H3), VE was poorer for those vaccinated in the current and prior seasons.

KEYWORDS:

Australia; epidemiology; influenza; influenza-like illness - ILI; surveillance; vaccines and immunisation; viral infections

[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Ingenta plc Icon for PubMed Central
Loading ...
Support Center